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Abstract
Purpose We conducted a pilot study to prospectively evaluate
the efficacy of PET/CTwith 11C-choline (choline PET/CT) for
primary diagnosis and staging of urothelial carcinoma of the
upper urinary tract (UUT-UC).
Methods Enrolled in this study were 16 patients (9 men, 7
women; age range 51 – 83 years, mean±SD 69±10.8 years)
with suspectedUUT-UC. The patientswere examined by choline
PET/CT, and 13 underwent laparoscopic nephroureterectomy
and partial cystectomy. Lymphadenectomy and chemotherapy
were also performed as necessary in some of the patients. Of the
16 patients, 12 were confirmed to have UUT-UC (7 renal pelvis
carcinoma and 5 ureteral carcinoma), 1 had malignant lympho-
ma (ureter), 1 had IgG4-related disease (ureter), and 2 had other
benign diseases (ureter).
Results Of the 16 study patients, 13 showed definite choline
uptake in urothelial lesions, and of these, 11 had UUT-UC, 1
had malignant lymphoma, and 1 had IgG4-related disease.
Three patients without choline uptake comprised one with
UUT-UC and two with benign diseases. Of the 12 patients
withUUT-UC, 3 had distant metastases, 2 hadmetastases only
in the regional lymph nodes, and 7 had no metastases. Distant
metastases and metastases in the regional lymph nodes
showed definite choline uptake. The outcome in patients with
UUT-UC, which was evaluated 592 – 1,530 days after sur-
gery, corresponded to the patient classification based on the
presence or absence of metastases and locoregional or distant
metastases. Choline uptake determined as SUVmax 10 min
after administration was significantly higher than at 20 min in
metastatic tumours of UUT-UC (p<0.05), whereas there was
no statistically significant difference between the SUVmax
values at 10 and those at 20 min in primary tumours of
UUT-UC.
Conclusion This study suggests that choline PET/CT is a
promising tool for the primary diagnosis and staging of
UUT-UC.
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Introduction
Urothelial carcinoma of the upper urinary tract (renal pelvis
and ureter; UUT-UC) is an infrequent genitourinary malig-
nancy accounting for 5 % of urothelial cancers and less than
10 % of renal tumours [1]. Analysis of epidemiological and
survival patterns of UUT-UC over the past 30 years in a
review of a large, population-based database in the USA has
shown that the incidence of UUT-UC has slowly risen, and
that increasing patient age, male gender, Afro-American race,
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bilateral UUT-UC and regional/distant disease are all associ-
ated with poorer survival [2].
For the primary diagnosis and staging of UUT-UC, radio-
graphic imaging by intravenous and retrograde pyelography
and CT scanning, ureteroscopic visualization and biopsy of
the tumour, and urine cytology are usually performed.
Although 18F-FDG is the radiopharmaceutical most frequent-
ly used in PET, FDG is not a useful tracer for the detection of
primary tumours of the urinary tract because of its renal
excretion. Therefore, the utility of FDG PET in the detection
of urinary tract tumours is limited to distant metastases [3, 4].
It has been reported that FDG PET/CT is superior to conven-
tional evaluations in detecting occult metastases in patients
with invasive bladder cancer [5, 6]. However, another study
has shown no advantage of FDG PET/CT over CT alone for
lymph node staging in invasive bladder cancer [7].
A number of studies have demonstrated that PET/CT with
11C-choline (choline PET/CT) is useful in the detection of
lymph node metastases of prostate cancer [8–15] and also the
detection of primary prostate cancer with certain limitations
[16–20]. However, to the best of our knowledge, there have
been no studies on the efficacy of choline PET/CT in the initial
diagnosis and local staging of UUT-UC. The purpose of this
pilot study was to prospectively evaluate the impact of choline
PET/CT in localizing the primary tumour and staging of UUT-
UC. In this study, the effects of the choline PET/CT findings
on the clinical management of UUT-UC and the outcomes in
patients with UUT-UC were also evaluated.
Materials and methods
Patients
All procedures followed the clinical guidelines of our hospital
and were approved by the institutional review board. A com-
plete description of the study was given to all participating
patients and a consent form was signed by the patients. We
enrolled 16 consecutive patients with a clinical suspicion of
UUT-UC (9 men, 7 women; age range 51 – 83 years, mean±
SD 69±10.8 years) who were referred to the Department of
Urology of our hospital between March 2008 and January
2011. All patients were examined using choline PET/CT
3 – 65 days (mean 19.2 days) before surgery. The patients
were classified clinically according to the 2009 TNM staging
system [21]. Two patients were inoperable and one patient
needed no surgery; all remaining patients underwent laparo-
scopic nephroureterectomy together with partial cystectomy
(LNUx). In the patients who were diagnosed with lymph node
metastases, lymphadenectomy was performed. In addition,
after choline PET/CT some of the patients received neoadju-
vant chemotherapy with gemcitabine and cisplatin [22, 23]
and chemotherapy with methotrexate, vinblastine,
doxorubicin and cisplatin, with gemcitabine and carboplatin,
and with gemcitabine .
Choline PET/CT image acquisition
PET and CT imaging was performed using a combined PET/
CT system (Biograph Sensation 16; Siemens Medical
Solutions, Forchheim, Germany, and Hoffman Estates, IL).
The system combines a full-ring PET scanner equipped with
lutetium orthosilicate crystal detectors and a 16-slice high-
resolution spiral CT scanner. All patients were examined after
fasting for 6 h. Choline PET/CTwas performed 10 and 20min
after intravenous injection of 3.7 MBq/kg of 11C-choline. In
the PET/CT scanner, the patients were positioned head first
and supine. Their arms were down and their hands were
clasped on the abdomen throughout the scanning procedure
rather than elevated above the head. This position was chosen
in consideration of patient comfort. First, a topogram was
acquired to define the imaging range for both CT and PET.
The range was typically chosen to extend from the scull base
to the mid-thigh level. A single nonenhanced continuous
spiral multislice CT scan was performed (120 kVp tube volt-
age, 100 mAs effective tube current, 16 × 1.5-mm detector
configuration, gantry rotation time 420 ms, 30-mm table feed
per rotation). The dose was adjusted to the actual level of
attenuation. For this purpose, attenuation was measured dur-
ing the first half of helical rotation, and the effective tube
current was automatically modulated for the second half
(CARE Dose; Siemens Medical Solutions, Hoffman Estates,
IL). Data were acquired for 1 min per bed position following
the CT scan. In all patients scanning was started caudally and
progressed cranially. The mean radiation doses used in this
study were 1.1 mSv in choline PET and 7.05 mSv in CT.
CT and PET images were reconstructed using standard
clinical protocols. CT images with a matrix size of
512 × 512 and a slice thickness of 3 mm with a 1.5-mm
increment were generated using filtered back-projection.
PET images with a matrix size of 128 × 128 were reconstruct-
ed using a 3-D numerical reconstruction algorithm (e.soft;
Siemens Medical Solutions). CT-derived attenuation maps
were used for PET attenuation correction.
PET/CT data analysis
For visual and quantitative analysis, images were displayed on
a clinical image analysis workstation that allowed interactive
exploration of CT, PET and fused PET/CT image data. The
loci where choline uptake was visibly higher than the activity
of adjacent areas were tentatively considered uptake-positive.
For each uptake-positive locus the intensity of uptake was
further analysed semiquantitatively. For this purpose the cor-
onal slice that contained the maximum uptake was selected
and the maximum standardized uptake value (SUVmax) with
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regard to body weight was determined. In this study, it was
demonstrated that, when SUVmax was lower than 2.2, the
contour and extent of the uptake area were vague. Therefore,
SUVmax 2.2 was considered negative uptake. The size of
tumours (long diameter×short diameter×height) was mea-
sured on CT images.
Histopathological typing
Histopathological examinations were performed in 14 of the
16 study patients. In 13 patients specimens were obtained
from tissue resected during LNUx and in 1 patient from tissue
obtained at autopsy. Histological grades were classified ac-
cording to the World Health Organization classification [24].
Statistical analysis
Kaplan-Meier analysis was used to compare the survival of
the patients with UUT-UC in relation to the presence and
location of metastases. The analyses were performed with
the log-rank test using SPSS v. 20 (IBM, Armonk, NY). The
SUVmax at 10 and 20 min after injection were compared
using the paired t-test. A value of p <0.05 was considered
significant.
Results
The profiles of the 16 study patients, and the choline uptake
determined as SUVmax and the sizes estimated onCT images of
the primary tumours are shown in Table 1. The clinical findings,
treatment, and outcomes in the patients, and histopathological
findings of the primary tumours are shown in Table 2.
Of the 16 study patients, 13 were choline uptake-positive
and the other 3 were uptake-negative in the urothelial lesions
(Table 1). In the three choline uptake-negative patients, the
SUVmax values were <2.2 at both 10 and 20 min. Except for
two inoperable patients and one patient who needed no sur-
gery, all patients underwent LNUx. The specimens obtained
by LNUx or autopsy (patient 2) were examined histopatho-
logically, which confirmed that of the 13 choline uptake-
positive patients, 11 patients (patients 1, 2, 6 – 12, 14, and
16) had UUT-UC, 1 (patient 3) had malignant lymphoma, and
1 (patient 13) had IgG4-related disease (Table 2). Of the three
uptake-negative patients, two (patients 4 and 5) had no ma-
lignancies and 1 (patient 15) had UUT-UC (Table 2). Of the 2
patients with no malignancies, one (patient 4) underwent
LNUx, and the lesion was confirmed histopathologically to
be nonmalignant. The other patient (patient 5) did not undergo
LNUx, but no malignancy was diagnosed based on his local
and clinical findings. The uptake-negative patient with UUT-
UC (patient 15) underwent LNUx and the lesion was
Table 1 Patient profiles and 11C-choline uptake and sizes of primary tumours estimated on PET/CT images
Patient no. Age (years) Sex Primary tumour
Side Location 11C-Choline uptake (SUVmax) Size (mm)a
10 min 20 min
1 61 M Right Renal pelvis 2.48 3.79 29×25×20
2 67 F Right Renal pelvis 5.52 4.36 37×26×20
3 50 F Left Ureter 2.80 2.94 10×9×12
4 73 F Right Ureter <2.2 <2.2 Indeterminableb
5 56 M Right Ureter <2.2 <2.2 15×15×15b
6 81 M Right Renal pelvis 3.83 3.43 19×25×12
7 83 M Right Renal pelvis 2.74 2.83 10×9×12
8 81 M Left Renal pelvis 2.31 3.22 8×8×15
9 69 F Left Renal pelvis 4.06 3.97 23×20×12
10 75 M Right Ureter 2.49 2.18 10×9×8
11 64 F Right Ureter 6.09 6.28 11×10×8
12 53 M Right Renal pelvis 7.85 8.08 46×45×40
13 56 F Right Ureter 3.25 2.64 12×11×12
14 81 M Left Ureter 3.97 3.79 10×10×10
15 67 F Right Ureter <2.2 <2.2 14×14×50
16 81 M Right Ureter 6.59 3.80 25×17×25
a Long diameter×short diameter×height
b Nonmalignancy
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confirmed histopathologically to be UUT-UC. Of the 12 pa-
tients with UUT-UC, 7 had renal pelvis carcinoma and 5 had
ureteral carcinoma (Table 1). In 6 of the 11 choline uptake-
positive patients with UUT-UC, the SUVmax at 10 min was
higher than at 20 min, and in 5 of these patients the SUVmax
at 20 min was higher than at 10 min. There was no statistically
significant difference between the SUVmax values of the
urothelial lesions at 10 min and those at 20 min.
One patient was false-negative for UUT-UC (patient 15).
The other 12 patients with UUT-UC showed choline SUVmax
ranging from 2.48 to 7.85 (mean±SD 4.15±1.73) at 10 min
and from 2.83 to 8.08 (3.95±1.54) at 20 min, and a patient
with malignant lymphoma in the left ureter (patient 3) also
showed choline uptake (SUVmax 2.80 at 10 min and 2.94 at
20 min; Tables 1 and 2). There was incidentally a patient with
IgG4-related disease [25, 26] who had a tumorous lesion in
the right ureter (patient 13), and the lesion showed weak but
definite choline uptake (SUVmax 3.25 at 10 min and 2.64 at
20 min; Tables 1 and 2). The sensitivity of choline PET/CT in
the detection of UUT-UC was 92 % (11 of 12 patients). The
nonmalignant tumorous ureteral lesion associated with IgG4-
related disease with positive uptake was considered false-
positive as judged only on the basis of malignancy or
nonmalignancy, whereas the other two nonmalignant ureteral
lesions in patients 4 and 5 were uptake-negative.
In 5 of the 12 patients with UUT-UC (patients 2, 11, 12, 14
and 16) choline PET/CT also showed definite choline uptake
in the sites corresponding to metastases, patients 11 and 14
had metastases only in the regional lymph nodes, and patients
2, 12 and 16 also had distant metastases (Table 3). These
metastatic lesions were detected first by choline PET/CT
performed in this study. Choline uptake in the metastatic
lesions was determined as SUVmax and the size of the lesions
was estimated on CT images (Table 3). The SUVmax values
in the metastatic lesions were as high as in the primary
tumours, ranging from 2.55 to 10.39 (5.75±1.85) at 10 min
and from 2.28 to 11.80 (5.45±2.10) at 20 min.
In 10 of 15 choline uptake-positive metastatic lesions, the
SUVmax values at 10min were higher than those at 20min, in
4 the SUVmax values at 20 min were higher than those at
10 min, and in 1 the SUVmax values at 10 and 20 min were
equal. The SUVmax values at 10 min were significantly
higher than those at 20 min (p<0.05). The size of the largest
metastatic tumours (41×33×40 mm, left aortic lymph nodes
in patient 16) approximated that of the primary tumour (46×
45×40 mm, right renal pelvis in patient 12). In one inoperable





Treatment Interval from PET/CT
to LNUx (days)
Histopathological findings Outcome Days after LNUxb
1 III (T3N0M0) LNUx 33 UC, G2>G3 pT3, ly0, v0, n0 NED 1,530
2 IV (T4N2M1) Inoperable – UC, G3, pT4 Died from cancer 25 (after PET/CT )
3 I (T1N0M0) LNUx 45 Malignant lymphoma NED 1,560
4 – LNUx 10 No malignancy NED 699
5 – – – – NED –
6 0a (T1aN0M0) LNUx 14 UC, G1, pTa, ly0, n0, v0 Died from cancer 725
7 I (T1N0M0) LNUx 7 UC, G2, pT1, ly0, n0, v0 NED 1,451
8 I (T1N0M0) LNUx 13 UC, G2, pT1, ly0, n0, v0 NED 1,426
9 II (T2N0M0) LNUx 42 UC, G2=G3, pT2, ly0, v0, n0 NED 1,402
10 I (T1N0M0) LNUx 45 UC, G2>G3, pT1, ly0, v0, n0 NED 1,399
11 IV (T2N1M0) NAC+LNUx+MVAC 4 UC, G2-3, pT2, ly+, v+, n+ NED 1,414
12 IV (T4N0M1) LNUx+MVAC 65 UC>SCC, G3, pT4 Died from cancer 180
13 – LNUx 3 IgG4-related disease NED 743
14 IV (T3N1M0) LNUx+(G+CBDCA) 3 UC, G3, pT3, INFβ, ew0, ly0, n0 Died from cancer 600
15c IV (T4N0M0) LNUx+NAC 61 UC, G3, pT4, INFβ, ly2, v1,n0 Alive with cancer 592
16 IV (T3N2M1) Inoperable, G – – Alive with cancer 510 (after PET/CT)
LNUx laparoscopic nephroureterectomy and partial cystectomy; NAC neoadjuvant chemotherapy with gemcitabine and cisplatin (two cycles) before or
after LNUx; NED no evidence of disease
Chemotherapy: MVAC methotrexate, vinblastine, doxorubicin, and cisplatin (three cycles) after LNUx; G+CBOCA gemcitabine and carboplatin
(three cycles) after LNUx; G gemcitabine (three cycles)
a According to Sobin et al. [21]
b Interval (days) between LNUx and 14 July or 10 September 2012. If patient died, interval between LNUx and death. In patients who underwent no
LNUx, interval between PET/CTand 14 July or 10 September 2012 or deathcMetastases in the sacral lymph nodes and 4th lumber spine were found 380
days after LNUx
cMetastases in the sacral lymph nodes and 4th lumber spine were found 380 days after LNUx
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patient (patient 2), metastases were found in the skull, sixth
thoracic spine, pelvis, left lung, and the right lower
paratracheal and subaortic lymph nodes; in another inoperable
patient (patient 16), metastases were found in the left
supraclavicular lymph nodes and the left anterior mediastinal
lymph nodes as well as in the regional lymph nodes including
the left aortic and common iliac lymph nodes (Table 3). The
metastatic tumours in the regional and distant lymph nodes
were surgically resected (patients 11, 12 and 14) except in two
inoperable patients (patients 2 and 16).
The outcome in all 16 study patients was checked on 14 July
or 10 September 2012 (592 – 1,530 days after LNUx; Table 2).
The outcomes in patients with distant metastases, with metasta-
ses only in the regional lymph nodes, andwithout metastases are
compared in Table 4 and Fig. 1. An inoperable patient (patient 2)
died from cancer 25 days after choline PET/CT and another
inoperable patient (patient 16) was alive with cancer 510 days
after choline PET/CT. Of the other two patients with metastases
only in the regional lymph nodes, one (patient 14) died from
cancer 600 days after LNUx, and one (patient 11) had no
evidence of disease 1,414 days after LNUx. Of seven patients
with UUT-UC without metastases, five (patients 1, 7, 8, 9 and
10) had no evidence of disease 1,399 – 1,530 days after LNUx,
one (patient 6) died from another cause 725 days after LNUx,
and one (patient 15) was alive with cancer 592 days after LNUx,
although in this patient metastases in the sacral lymph nodes and
fourth lumbar spine were found 380 days after surgery (the
footnote relating to patient 15 in Table 2). Patients with malig-
nant lymphoma (patient 3) or with IgG4-related disease (patient
13) had no evidence of disease 1,560 and 743 days after LNUx.
PET/CT images of the primary and metastatic tumours and
the photographs of the primary tumours after resection in
patients 1, 12 and 11 are shown in Figs. 2, 3 and 4.
Discussion
11C-Choline is a small molecule that after intravenous injec-
tion is very quickly integrated into the cell membrane as
Table 4 Outcomes in patients with distant metastases, with metastases only in regional lymph nodes, and without metastases







With distant metastases 2 (patients 2, 16) No surgery 1b 1e
1 (patient 12) LNUx + lymphadenectomy 1c
With metastases only in regional
lymph nodes
2 (patients 11, 14) LNUx + lymphadenectomy 1d 1
Without metastases 6 (patients 1, 7, 8, 9, 10, 15)a 1f 5
LNUx laparoscopic nephroureterectomy and partial cystectomy
a Seven patients had no metastases, but one died from another cause and was excluded
bDied from cancer 25 days after PET/CT
cDied from cancer 180 days after LNUx
dDied from cancer 600 days after LNUx
e Judged 510 days after PET/CT
f See the footnote relating to patient 15 in Table 2
g Judged 743 – 1,530 days after LNUx
Table 3 Properties of metastatic lesions
Patient no. Location SUVmax Size (mm)a
10 min 20 min
2 Right lower paratracheal LN 5.09 4.57 28×21×14
Subaortic LN 5.39 4.41 17×12×10
Thoracic spine (VI) 5.10 4.71 17×15×12
Right iliac bone 9.29 7.60 35×33×20
Left lung 2.55 2.28 21×17×16
Skull 5.07 4.40 16×13×16
11 Right internal iliac LN 4.92 5.22 11×10×9
12 Right renal hilar LN 4.68 3.57 21×10×12
Thoracic spine (VI) 6.45 6.01 19×16×14
Thoracic spine (XII) 7.36 7.55 36×30×26
Right iliac bone 10.39 11.80 28×25×16
14 Left sacral LN 4.73 5.15 10×10×10
16 Left aortic LN 5.07 5.46 41×33×40
Left common iliac LN 5.85 5.85 30×17×35
Left supraclavicular LN 5.91 4.73 20×10×10
Left anterior mediastinal LN 4.16 3.82 10×10×10
LN lymph node
a Long diameter×short diameter×height
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phosphatidylcholine. It is a marker of membrane metabolism,
and is subject to very late urinary excretion, so that the renal
pelvis and ureter are free of urinary radioactivity at the time of
image acquisition. Nevertheless, there have been no studies so
far on the efficacy of choline PET/CT in the detection of the
primary tumour and metastases of UUT-UC; this was the
principal motive for performing this study.
Of the 16 study patients with suspicion of UUT-UC exam-
ined in the present study, in 12 UUT-UC was confirmed. Of
the other four, one had malignant lymphoma, one had IgG4-
related disease, and two had benign diseases. Of the 12 pa-
tients with UUT-TC, 11 (92 %) were choline uptake-positive
and the other 1 was false-negative on choline PET/CT. The



















Fig. 1 Kaplan-Meier survival
curves showing survival in
patients with distant metastases
(three patients), with metastases
only in the regional lymph nodes
(two patients), and without
metastases (six patients). See the
footnotes to Tables 2 and 4
a b
c
Fig. 2 Urothelial carcinoma of
the left renal pelvis in patient 1. a,
b Choline PET/CT images of the
primary tumour at 10 min (a) and
20min (b) after injection. Choline
uptake at 10 min is positive but
weak (SUVmax 2.48) compared
with that at 20 min (SUVmax
3.79). c Photograph of the
primary tumour after resection.
Circles tumour sites
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related disease were uptake-positive, and the two patients with
nonmalignant diseases were uptake-negative.
Malignant cells have elevated levels of choline and upreg-
ulation of choline kinase activity [27–30]. Studies have been
conducted to evaluate the ability and usefulness of choline
PET/CT in detecting cancer within the prostate and in differ-
entiating cancer from normal tissue and/or benign disease
[16–19]. In summary, these studies indicate that the use of
choline PET/CT for initial diagnosis and local staging of
prostate cancer cannot be recommended as a first-line screen-
ing method in men at high risk of prostate cancer [20]. In
contrast, there have been a number of studies demonstrating
that choline PET/CT is useful in detecting and staging lymph
node metastases of prostate cancer [8–15]. In another study
evaluating the ability of choline PET to detect bladder cancer
before cystectomy, normal bladder showed little uptake, and
primary bladder cancer was visualized in 10 of 18 patients
with residual invasive disease in the cystectomy specimen
[31].
Of the 12 patients with UUT-UC examined in the present
study, choline PET/CT revealed distant metastases in three,
metastases only in the regional lymph nodes in two, and no
metastases in seven. Both distant metastatic lesions and re-






Fig. 3 Urothelial carcinoma of
the right renal pelvis in patient 12.
a Choline PET/CT images of the
primary tumour at 10 min after
injection (SUVmax 7.85). b
Photograph of the primary tumour
after resection. Circles tumour
sites. c, d Choline PET/CT
images of the metastatic lesions at
the 12th thoracic spine (SUVmax
7.36, c) and the right iliac bone
(SUVmax 10.39, d) at 10 min
after injection. Arrows bone
metastases. eMaximum intensity
projection image. The metastatic
lesions in the sixth thoracic spine
and the right iliac bone are seen
(arrows)
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and similar SUVmax to the values in the primary tumours of
UUT-UC. According to the diagnostic findings on choline
PET/CT, one of three patients with distant metastases and
two patients with metastases only in the regional lymph
nodes underwent LNUx and lymphadenectomy, and seven
patients without metastases underwent LNUx. As shown in
Table 4 and Fig. 1, the outcome in patients with UUT-UC
corresponded to the patient classification based on the pres-
ence or absence of metastases and locoregional or distant
metastases. These results suggest that choline PET/CT is
useful in staging as well as in the primary diagnosis of
UUT-UC.
Choline uptakes determined as SUVmax at 10 min were
significantly higher than those at 20min in metastatic tumours
of UUT-UC (p<0.05), whereas these was no statistically
significant difference between the SUVmax values at 10 min
and those at 20 min in the primary tumours of UUT-UC.
Although the reason for the difference between the primary
and metastatic tumours of UUT-UC is not yet known, the
finding suggests that choline uptake takes place earlier in
metastatic tumours than in primary tumours of UUT-UC.
The results indicate that choline uptake should be determined
at both 10 and 20 min after injection for the detection of the





Fig. 4 Urothelial carcinoma of
the right ureter in patient 11. a
Choline PET/CT images of the
primary tumour at 10 min after
injection (SUVmax 6.09). b
Photograph of the primary tumour
after resection. Circle tumour site.
c Choline PET/CT images of the
metastatic lesions at the right
internal iliac lymph nodes at
10 min after injection (SUVmax
4.92). dMaximum intensity
projection image. Arrows tumour
sites. A catheter is inserted into
the right ureter (a, d)
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number of patients assessed in this pilot study was rather
small, confirmation of this conclusion must await further
follow-up studies with greater numbers of patients.
Besides UUT-UC, the tumours developed in the ureter of a
patient with malignant lymphoma and a patient with IgG4-
related disease were choline uptake-positive. IgG4-related
disease, which is characterized by elevated serum IgG4 con-
centrations and tumefaction or tissue infiltration with IgG4-
positive plasma cells, is an under-recognized condition about
which knowledge is now growing rapidly [25, 26]. The pres-
ent study demonstrated that inflammatory pseudotumour de-
veloped in the ureter of a patient with IgG4-related disease and
the tumour showed definite choline uptake. To our knowledge
there have been no prior reports of definite choline uptake in
tumorous lesions associated with IgG4-related disease.
Conclusion
The results of the present study showed that choline PET/CT
is useful in detecting the primary tumours and metastases of
UUT-UC and potentially in providing valuable prognostic
information. Besides UUT-UC, the ureteral tumours associat-
ed with malignant lymphoma and IgG4-related disease
showed definite choline uptake. Follow-up studies with great-
er numbers of patients are needed to make the conclusions
more reliable.
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